Drugs that contain Ponesimod
1. List of Ponvory drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| USRE43728 | JANSSEN PHARMS | Thiazolidin-4-one derivatives |
Nov, 2024
(1 year, 9 months from now) | |
| US9062014 | JANSSEN PHARMS | Crystalline forms of (R)-5-[3-chloro-4-(2,3-dihydroxy-propoxy)-benz[Z]ylidene]-2-([Z]-propylimino)-3-0-tolyl-thiazolidin-4-one |
May, 2032
(9 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9000018 | JANSSEN PHARMS | Thiazolidin-4-one-derivatives |
Nov, 2024
(1 year, 9 months from now) | |
| US8273779 | JANSSEN PHARMS | Thiazolidin 4-one derivatives |
Dec, 2025
(2 years from now) | |
| US10220023 | JANSSEN PHARMS | Dosing regimen for a selective S1P1 receptor agonist |
Dec, 2035
(12 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Mar 18, 2026 |
NCE-1 date: March, 2025
Market Authorisation Date: 18 March, 2021
Treatment: Reduction of circulating lymphocytes in treating relapsing forms of multiple sclerosis (ms), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults; Treatment of relapsing forms of multiple sclerosis (ms), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults; Treatment of relapsing forms of multiple sclerosis (ms), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults using a dose titration schedule followed by a maintenance dose
Dosage: TABLET;ORAL
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic